Hostname: page-component-5c6d5d7d68-vt8vv Total loading time: 0.001 Render date: 2024-08-24T07:22:14.603Z Has data issue: false hasContentIssue false
  • English
  • Français

To the Editor Correspondence

Published online by Cambridge University Press:  02 December 2014

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Other
Information
Canadian Journal of Neurological Sciences , Volume 34 , Issue 1 , February 2007 , pp. 108
Copyright
Copyright © The Canadian Journal of Neurological 2007

References

1. Hunter, GR, Donat, J, Pryse-Phillips, W, Harder, S, Robinson, CA. Rasmussen’s encephalitis in a 58-year-old female: still a variant? Can J Neurol Sci. 2006; 33(3):302–5.Google Scholar
2. Howard, JF Jr. Intravenous immunoglobulin for the treatment of acquired myasthenia gravis. Neurology. 1998; 51(6 Suppl 5): S30–6.Google Scholar
3. Dalakas, MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology. 2002; 59(12 Suppl 6): S13–21.CrossRefGoogle ScholarPubMed
4. Krolick, KA, Zoda, TE, Thompson, PA. Examination of characteristics that may distinguish disease-causing from benign AChR-reactive antibodies in experimental autoimmune myasthenia gravis. Adv Neuroimmunol. 1994; 4(4):475–93.Google Scholar